Literature DB >> 31383730

APOL1 Kidney Risk Variants and Cardiovascular Disease: An Individual Participant Data Meta-Analysis.

Morgan E Grams1,2,3, Aditya Surapaneni2,3, Shoshana H Ballew2,3, Lawrence J Appel2,3, Eric Boerwinkle4, L Ebony Boulware5, Teresa K Chen6,2, Josef Coresh2,3, Mary Cushman7,8, Jasmin Divers9, Orlando M Gutiérrez7,10, Marguerite R Irvin7,10, Joachim H Ix11,12, Jeffrey B Kopp13, Lewis H Kuller14, Carl D Langefeld9, Michael S Lipkowitz15, Kenneth J Mukamal16, Solomon K Musani17, Rakhi P Naik18, Nicholas M Pajewski9, Carmen A Peralta19,20,21, Adrienne Tin2,3, Christina L Wassel22, James G Wilson23, Cheryl A Winkler24, Bessie A Young25,26, Neil A Zakai7,8, Barry I Freedman27.   

Abstract

BACKGROUND: Two coding variants in the apo L1 gene (APOL1) are strongly associated with kidney disease in blacks. Kidney disease itself increases the risk of cardiovascular disease, but whether these variants have an independent direct effect on the risk of cardiovascular disease is unclear. Previous studies have had inconsistent results.
METHODS: We conducted a two-stage individual participant data meta-analysis to assess the association of APOL1 kidney-risk variants with adjudicated cardiovascular disease events and death, independent of kidney measures. The analysis included 21,305 blacks from eight large cohorts.
RESULTS: Over 8.9±5.0 years of follow-up, 2076 incident cardiovascular disease events occurred in the 16,216 participants who did not have cardiovascular disease at study enrollment. In fully-adjusted analyses, individuals possessing two APOL1 kidney-risk variants had similar risk of incident cardiovascular disease (coronary heart disease, myocardial infarction, stroke and heart failure; hazard ratio 1.11, 95% confidence interval, 0.96 to 1.28) compared to individuals with zero or one kidney-risk variant. The risk of coronary heart disease, myocardial infarction, stroke and heart failure considered individually was also comparable by APOL1 genotype. APOL1 genotype was also not associated with death. There was no difference in adjusted associations by level of kidney function, age, diabetes status, or body-mass index.
CONCLUSIONS: In this large, two-stage individual participant data meta-analysis, APOL1 kidney-risk variants were not associated with incident cardiovascular disease or death independent of kidney measures.
Copyright © 2019 by the American Society of Nephrology.

Entities:  

Keywords:  APOL1; Blacks; cardiovascular disease; death; kidney disease; meta-analysis

Mesh:

Substances:

Year:  2019        PMID: 31383730      PMCID: PMC6779370          DOI: 10.1681/ASN.2019030240

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   14.978


  30 in total

1.  Association of trypanolytic ApoL1 variants with kidney disease in African Americans.

Authors:  Giulio Genovese; David J Friedman; Michael D Ross; Laurence Lecordier; Pierrick Uzureau; Barry I Freedman; Donald W Bowden; Carl D Langefeld; Taras K Oleksyk; Andrea L Uscinski Knob; Andrea J Bernhardy; Pamela J Hicks; George W Nelson; Benoit Vanhollebeke; Cheryl A Winkler; Jeffrey B Kopp; Etienne Pays; Martin R Pollak
Journal:  Science       Date:  2010-07-15       Impact factor: 47.728

2.  Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis.

Authors:  Kunihiro Matsushita; Marije van der Velde; Brad C Astor; Mark Woodward; Andrew S Levey; Paul E de Jong; Josef Coresh; Ron T Gansevoort
Journal:  Lancet       Date:  2010-05-17       Impact factor: 79.321

3.  The MYH9/APOL1 region and chronic kidney disease in European-Americans.

Authors:  Conall M O'Seaghdha; Rulan S Parekh; Shih-Jen Hwang; Man Li; Anna Köttgen; Josef Coresh; Qiong Yang; Caroline S Fox; W H Linda Kao
Journal:  Hum Mol Genet       Date:  2011-03-23       Impact factor: 6.150

4.  Association of APOL1 With Heart Failure With Preserved Ejection Fraction in Postmenopausal African American Women.

Authors:  Nora Franceschini; Jeffrey B Kopp; Ana Barac; Lisa W Martin; Yun Li; Huijun Qian; Alex P Reiner; Martin Pollak; Robert B Wallace; Wayne D Rosamond; Cheryl A Winkler
Journal:  JAMA Cardiol       Date:  2018-08-01       Impact factor: 14.676

5.  APOL1 Risk Variants and Cardiovascular Disease: Results From the AASK (African American Study of Kidney Disease and Hypertension).

Authors:  Teresa K Chen; Lawrence J Appel; Morgan E Grams; Adrienne Tin; Michael J Choi; Michael S Lipkowitz; Cheryl A Winkler; Michelle M Estrella
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-06-01       Impact factor: 8.311

Review 6.  APOL1 Gene Kidney Risk Variants and Cardiovascular Disease: Getting to the Heart of the Matter.

Authors:  Nicholas O McLean; Todd W Robinson; Barry I Freedman
Journal:  Am J Kidney Dis       Date:  2017-01-28       Impact factor: 11.072

7.  APOL1 nephropathy risk variants do not associate with subclinical atherosclerosis or left ventricular mass in middle-aged black adults.

Authors:  Orlando M Gutiérrez; Sophie Limou; Feng Lin; Carmen A Peralta; Holly J Kramer; J Jeffrey Carr; Kirsten Bibbins-Domingo; Cheryl A Winkler; Cora E Lewis; Jeffrey B Kopp
Journal:  Kidney Int       Date:  2017-10-14       Impact factor: 18.998

8.  Apolipoprotein L1 gene variants associate with prevalent kidney but not prevalent cardiovascular disease in the Systolic Blood Pressure Intervention Trial.

Authors:  Carl D Langefeld; Jasmin Divers; Nicholas M Pajewski; Amret T Hawfield; David M Reboussin; Diane E Bild; George A Kaysen; Paul L Kimmel; Dominic S Raj; Ana C Ricardo; Jackson T Wright; John R Sedor; Michael V Rocco; Barry I Freedman
Journal:  Kidney Int       Date:  2014-07-16       Impact factor: 10.612

9.  Renal and Cardiovascular Morbidities Associated with APOL1 Status among African-American and Non-African-American Children with Focal Segmental Glomerulosclerosis.

Authors:  Robert P Woroniecki; Derek K Ng; Sophie Limou; Cheryl A Winkler; Kimberly J Reidy; Mark Mitsnefes; Matthew G Sampson; Craig S Wong; Bradley A Warady; Susan L Furth; Jeffrey B Kopp; Frederick J Kaskel
Journal:  Front Pediatr       Date:  2016-11-17       Impact factor: 3.418

10.  Increased burden of cardiovascular disease in carriers of APOL1 genetic variants.

Authors:  Kaoru Ito; Alexander G Bick; Jason Flannick; David J Friedman; Giulio Genovese; Michael G Parfenov; Steven R Depalma; Namrata Gupta; Stacey B Gabriel; Herman A Taylor; Ervin R Fox; Christopher Newton-Cheh; Sekar Kathiresan; Joel N Hirschhorn; David M Altshuler; Martin R Pollak; James G Wilson; J G Seidman; Christine Seidman
Journal:  Circ Res       Date:  2013-12-30       Impact factor: 17.367

View more
  13 in total

1.  APOL1 Nephropathy Risk Variant Associations with Diseases beyond the Kidney: APOL1 and Sepsis.

Authors:  Lijun Ma; Barry I Freedman
Journal:  Clin J Am Soc Nephrol       Date:  2019-11-08       Impact factor: 8.237

2.  Apolipoprotein L1 Gene Testing Comes of Age.

Authors:  Barry I Freedman; Chris P Larsen
Journal:  Kidney360       Date:  2020-01-08

Review 3.  Kidney disease and APOL1.

Authors:  Aminu Abba Yusuf; Melanie A Govender; Jean-Tristan Brandenburg; Cheryl A Winkler
Journal:  Hum Mol Genet       Date:  2021-04-26       Impact factor: 6.150

Review 4.  A brief introduction of meta-analyses in clinical practice and research.

Authors:  Xiao-Meng Wang; Xi-Ru Zhang; Zhi-Hao Li; Wen-Fang Zhong; Pei Yang; Chen Mao
Journal:  J Gene Med       Date:  2021-03-25       Impact factor: 4.565

5.  APOL1 Genetic Variants Are Associated With Increased Risk of Coronary Atherosclerotic Plaque Rupture in the Black Population.

Authors:  Anne Cornelissen; Daniela T Fuller; Raquel Fernandez; Xiaoqing Zhao; Robert Kutys; Elizabeth Binns-Roemer; Marco Delsante; Atsushi Sakamoto; Ka Hyun Paek; Yu Sato; Rika Kawakami; Masayuki Mori; Kenji Kawai; Teruhiko Yoshida; Khun Zaw Latt; Clint L Miller; Paul S de Vries; Frank D Kolodgie; Renu Virmani; Myung Kyun Shin; Maarten Hoek; Jurgen Heymann; Jeffrey B Kopp; Avi Z Rosenberg; Harry R Davis; Liang Guo; Aloke V Finn
Journal:  Arterioscler Thromb Vasc Biol       Date:  2021-05-27       Impact factor: 10.514

6.  APOL1 at 10 years: progress and next steps.

Authors:  Barry I Freedman; Jeffrey B Kopp; Matthew G Sampson; Katalin Susztak
Journal:  Kidney Int       Date:  2021-03-29       Impact factor: 18.998

7.  Phenome-wide association analysis suggests the APOL1 linked disease spectrum primarily drives kidney-specific pathways.

Authors:  Archna Bajaj; Andrea Ihegword; Chengxiang Qiu; Aeron M Small; Wei-Qi Wei; Lisa Bastarache; QiPing Feng; Rachel L Kember; Marjorie Risman; Roy D Bloom; David L Birtwell; Heather Williams; Christian M Shaffer; Jinbo Chen; Regeneron Genetics Center; Joshua C Denny; Daniel J Rader; C Michael Stein; Scott M Damrauer; Katalin Susztak
Journal:  Kidney Int       Date:  2020-02-17       Impact factor: 10.612

Review 8.  The function of apolipoproteins L (APOLs): relevance for kidney disease, neurotransmission disorders, cancer and viral infection.

Authors:  Etienne Pays
Journal:  FEBS J       Date:  2020-06-25       Impact factor: 5.542

9.  APOL1 Risk Variants and Subclinical Cardiovascular Disease in Incident Hemodialysis Patients.

Authors:  Teresa K Chen; Jessica Fitzpatrick; Cheryl A Winkler; Elizabeth A Binns-Roemer; Celia P Corona-Villalobos; Bernard G Jaar; Stephen M Sozio; Rulan S Parekh; Michelle M Estrella
Journal:  Kidney Int Rep       Date:  2020-11-20

10.  APOL1 Risk Alleles, Cardiac Markers, and Risk of ESKD in African Americans: The Atherosclerosis Risk in Communities Study.

Authors:  Aditya L Surapaneni; Shoshana H Ballew; Josef Coresh; Christie M Ballantyne; Elizabeth Selvin; Kunihiro Matsushita; Morgan E Grams
Journal:  Kidney Med       Date:  2020-05-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.